Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 130
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
JDR Clin Trans Res ; 5(3): 278-283, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-31560579

RESUMEN

INTRODUCTION: Oral health mirrors systemic health; yet, few clinics worldwide provide dental care as part of primary medical care, nor are dental records commonly integrated with medical records. OBJECTIVES: To determine the degree to which misreporting of underlying health conditions poses problems for dental clinicians, we assessed misreporting of 2 common medical health conditions-hypertension and diabetes-at the time of dental examination and assessment. METHODS: Using comparative chart analysis, we analyzed medical records of a diverse group of patients previously seen at the University of Texas Physician outpatient practice and then treated at the University of Texas Health Science Center at Houston School of Dentistry. Electronic health records of patients aged ≥18 y were extracted from 2 databases: Allscripts (University of Texas Physician) and axiUm (University of Texas Health Science Center at Houston). We identified 1,013 patients with the commonly occurring conditions of diabetes, hypertension, or both, with nonintegrated records contained in Allscripts and axiUm. We identified the percentage of those patients previously diagnosed with diabetes and/or hypertension by their physicians who failed to report these conditions to their dental clinicians. RESULTS: Of those patients with diabetes, 15.1% misreported their diabetes condition to their dental clinicians, while 29.0% of patients with hypertension also misreported. There was no relationship between sex and misreporting of hypertension or diabetes, but age significantly affected reporting of hypertension, with misreporting decreasing with age. CONCLUSIONS: Because these conditions affect treatment planning in the dental clinic, misreporting of underlying medical conditions can have negative outcomes for dental patients. We conclude that policies that support the integration of medical and dental records would meaningfully increase the quality of health care delivered to patients, particularly those dental patients with underlying medical conditions. KNOWLEDGE TRANSFER STATEMENT: Our study illustrates an urgent need for policy innovation within a currently fragmented health care delivery system. Dental clinicians rely on the accuracy of health information provided by patients, which we found was misreported in ~15% to 30% of dental patient records. An integrated health care system can close these misreporting gaps. Policies that support the integration of medical and dental records can improve the quality of health care delivered, particularly for dental patients with underlying medical conditions.


Asunto(s)
Prestación Integrada de Atención de Salud , Registros Electrónicos de Salud , Instituciones de Salud , Humanos , Atención al Paciente , Atención Primaria de Salud
2.
Int J Organ Transplant Med ; 7(1): 9-18, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26889369

RESUMEN

BACKGROUND: Periodontitis is an important oral disease. Stem cell therapy has found its way in treatment of many diseases. OBJECTIVE: To evaluate the regenerative potential of periodontal ligament-derived stem cells (PDLSCs) and osteoblast differentiated from PDLSC in comparison with bone marrow-derived mesenchymal stem cells (BM-MSCs) and pre-osteoblasts in calvarial defects. METHODS: After proving the existence of surface markers by flow cytometry, BM-MSCs were differentiated into osteoblasts. 5 defects were made on rabbit calvaria. 3 of them were first covered with collagen membrane and then with BM-MSCs, PDLSCs, and pre-osteoblasts. The 4(th) defect was filled with collagen membrane and the 5(th) one was served as control. After 4 weeks, histological (quantitative) and histomorphological (qualitative) surveys were performed. RESULTS: Both cell lineages were positive for CD-90 cell marker, which was specifically related to stem cells. Alizarin red staining was done for showing mineral material. RT-PCR set up for the expression of Cbfa1 gene, BMP4 gene, and PGLAP gene, confirmed osteoblast differentiation. The findings indicated that although PDLSCs and pre-osteoblasts could be used for bone regeneration, the rate of regeneration in BM-MSCs-treated cavities was more significant (p<0.0001). CONCLUSION: The obtained results are probably attributable to the effective micro-environmental signals caused by different bone types and the rate of cell maturation.

3.
Int J Oral Maxillofac Surg ; 42(5): 562-8, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23219713

RESUMEN

This study was designed to compare bone regeneration of tissue-engineered bone from adipose-derived stem cell and autogenous bone graft in a canine maxillary alveolar cleft model. In this prospective clinical trial, mesenchymal stem cells (MSCs) were isolated from subcutaneous canine adipose tissue. Undifferentiated cells were incubated with a 3mm×3mm×3mm hydroxyapatite/beta-tricalcium phosphate scaffold, in specific osteogenic medium for 21 days. Four mongrel dogs were prepared by removal of two of the three incisors bilaterally and a 15mm defect in bone was created from crest to nasal floor. After healing, repair was followed by a tissue engineered bone graft from adipose-derived stem cells on one side and corticocancellous tibial auto graft on the other side. Bone regeneration was evaluated by histomorphometry on days 15 and 60 after implantation. The data were analysed with descriptive and t test methods (α=0.05). Bone formation on the autograft sides was higher than on the stem cell sides at 15 and 60 days, 45% and 96% versus 5% and 70%, respectively. Differences between the two groups at 15 and 60 days were significant (p=0.004 and 0.001, respectively). Although autograft is still the gold standard for bone regeneration, tissue engineered bone may provide an acceptable alternative.


Asunto(s)
Trasplante Óseo/patología , Fisura del Paladar/cirugía , Maxilar/cirugía , Células Madre Mesenquimatosas/fisiología , Grasa Subcutánea/citología , Ingeniería de Tejidos/métodos , Alveolectomía/métodos , Animales , Médula Ósea/patología , Regeneración Ósea/fisiología , Trasplante Óseo/métodos , Calcificación Fisiológica/fisiología , Técnicas de Cultivo de Célula , Diferenciación Celular/fisiología , Separación Celular , Colágeno/análisis , Medios de Cultivo , Modelos Animales de Enfermedad , Perros , Durapatita/química , Citometría de Flujo , Microscopía Electrónica de Rastreo , Osteoblastos/patología , Osteogénesis/fisiología , Estudios Prospectivos , Tibia/cirugía , Factores de Tiempo , Andamios del Tejido/química , Sitio Donante de Trasplante/cirugía , Trasplante Autólogo
4.
Indian J Dent Res ; 23(4): 509-13, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23257487

RESUMEN

PURPOSE: This study evaluates the effect of thermo-mechanical cycling (TMC) on the bond strength of a ceramic to three cobalt-chromium (Co-Cr) and two nickel-chromium (Ni-Cr) alloys. MATERIALS AND METHODS: One hundred metal-ceramic specimens were prepared. While half of the specimens from each metal-ceramic combination (n = 10) were tested after storage in water at 37°C for 24 hours, the other half were subjected to TMC before testing. The bond strength was evaluated by the flexural strength test according to ISO 9693:1999 (E) recommendations. RESULTS: TMC decreased the bond strength of the tested metal-ceramic systems as compared to the water storage (control groups) (P=0.04). Although metal alloys were significantly different from each other in their bond strength with porcelain (P<0.001), the effect of TMC on the various metal-ceramic systems was not significantly different (P=0.99). CONCLUSION: It may be concluded that base metal-ceramic bond strength is affected by aging and the effect is relatively the same for all the tested porcelain-metal systems.


Asunto(s)
Aleaciones de Cromo/química , Recubrimiento Dental Adhesivo , Porcelana Dental/química , Aleaciones de Cerámica y Metal/química , Óxido de Aluminio/química , Grabado Dental/métodos , Módulo de Elasticidad , Humanos , Ensayo de Materiales , Fenómenos Mecánicos , Docilidad , Estrés Mecánico , Propiedades de Superficie , Temperatura , Factores de Tiempo , Agua/química
5.
Int Endod J ; 44(6): 499-504, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21276017

RESUMEN

AIM: To determine mRNA expression levels of Nav 1.8 in inflamed pulps of rats. METHODOLOGY: Inflammation was induced by creating pulp exposures in rat incisors. Histopathological changes in the induced pulpitis were evaluated 1, 3, 7 and 10 days after exposure. Using real-time PCR, the relative mRNA expression levels of Nav 1.8 in the inflamed rat dental pulp was determined. RESULTS: At day 1, no inflammation was evident in the pulp tissue, whereas increased levels of inflammatory responses were identified at day 3 and day 7. No pulpal inflammation was evident in day 10 or in the control group. Nav 1.8 was expressed in the rat dental pulp and increased at day 3 and day 7. Time course study of dental pulp inflammation indicated that differences in relative mRNA expression levels of Nav 1.8 were correlated with the severity of inflammation. CONCLUSIONS: Nav 1.8 channels seem to be expressed significantly more under a temporal control so as to be associated with a severity of inflammation during pulpitis. As Nav 1.8 has been considered to have a role in neuropathic pain, its expression within dental pulp may contribute to the pathophysiology of tooth pain.


Asunto(s)
Pulpitis/metabolismo , ARN Mensajero/metabolismo , Canales de Sodio/metabolismo , Animales , Modelos Animales de Enfermedad , Inflamación/genética , Inflamación/metabolismo , Estudios Longitudinales , Masculino , Canal de Sodio Activado por Voltaje NAV1.8 , Ratas , Ratas Wistar , Canales de Sodio/genética
6.
Phytother Res ; 21(8): 768-70, 2007 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-17486681

RESUMEN

Phytoestrogens with a biological activity like estradiol are naturally found in many plants. This study was designed to investigate the effect of red clover, a phytoestrogen-rich member of the legume family (Trifolium pratense) on the development of atherosclerosis in male hyperlipidemic rabbits. Twenty rabbits were semi-randomly distributed into four groups of five each. Two groups received either normal diet or normal diet supplemented with red clover. Two other groups received similar diets to both of which 1% cholesterol was added. Dietary use of red clover (RC) in hyperlipidemic rabbits significantly decreased C-reactive protein (CRP), triglyceride (TG), total cholesterol and LDL-cholesterol (LDL-C) whereas, HDL-cholesterol (HDL-C) was significantly increased in those animals (p < 0.05). Fatty streak formation was also significantly lower in aorta and left and right coronary arteries in the same animals due to use of dietary RC supplementation. These findings suggest that dietary RC may reduce cardiovascular risk factors.


Asunto(s)
Aterosclerosis/complicaciones , Aterosclerosis/dietoterapia , Dieta , Hipercolesterolemia/complicaciones , Hipercolesterolemia/dietoterapia , Trifolium/química , Animales , HDL-Colesterol , Vasos Coronarios/efectos de los fármacos , Vasos Coronarios/patología , Masculino , Conejos
7.
Pediatr Res ; 50(5): 604-10, 2001 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11641455

RESUMEN

Uteroplacental insufficiency causes intrauterine growth restriction (IUGR) and decreases plasma levels of the branched-chain amino acids in both humans and rats. Increased fetal oxidation of these amino acids may contribute to their decline in the IUGR fetus. The rate-limiting step of branched-chain amino acid oxidation is performed by the mitochondrial enzyme branched-chain alpha-keto acid dehydrogenase (BCKAD), which is regulated by a deactivating kinase. We therefore hypothesized that uteroplacental insufficiency increases BCKAD activity through altered mRNA and protein levels of BCKAD and/or the BCKAD kinase. In IUGR fetal liver, BCKAD activity was increased 3-fold, though no difference in hepatic BCKAD protein or mRNA levels were noted. Hepatic BCKAD kinase mRNA and protein levels were significantly decreased in association with the increase in BCKAD activity. In IUGR fetal skeletal muscle, BCKAD mRNA levels were significantly increased. IUGR skeletal muscle BCKAD protein levels as well as BCKAD kinase mRNA and protein levels were unchanged. We also quantified mRNA levels of two amino acid transporters: LAT1 (system L) and rBAT (cysteine and dibasic amino acids). Both hepatic and muscle LAT1 mRNA levels were significantly increased in the IUGR fetus. We conclude that uteroplacental insufficiency significantly increases hepatic BCKAD activity in association with significantly decreased mRNA and protein levels of the deactivating kinase. We speculate that these changes contribute to the decreased serum levels of branched-chain amino acids seen in the IUGR fetus and may be an adaptation to the deprived milieu associated with uteroplacental insufficiency.


Asunto(s)
Aminoácidos de Cadena Ramificada/metabolismo , Retardo del Crecimiento Fetal , Hígado/metabolismo , Músculo Esquelético/metabolismo , Insuficiencia Placentaria/metabolismo , Útero/fisiopatología , 3-Metil-2-Oxobutanoato Deshidrogenasa (Lipoamida) , Animales , Secuencia de Bases , Cartilla de ADN , Femenino , Cetona Oxidorreductasas/genética , Cetona Oxidorreductasas/metabolismo , Hígado/embriología , Hígado/enzimología , Complejos Multienzimáticos/genética , Complejos Multienzimáticos/metabolismo , Músculo Esquelético/embriología , Reacción en Cadena de la Polimerasa , Embarazo , Proteínas Quinasas/metabolismo , ARN Mensajero/metabolismo , Ratas
8.
J Nutr ; 131(6): 1682-6, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11385053

RESUMEN

Although it has been well established that starvation increases the oxidation of branched-chain keto acids (BCKA) in humans and experimental animals such as rats, the mechanism has not been adequately investigated. For example, the effects of starvation on protein and mRNA expressions of BCKA dehydrogenase, which is the key enzyme regulating this oxidation, have not yet been studied. To initiate such studies, we first determined the activity of BCKA dehydrogenase in the liver and skeletal muscle of fed and starved rats. The levels of activity of BCKA dehydrogenase were significantly greater in tissues of starved rats than in those of fed rats. We then investigated the possible mechanisms of these increases in enzyme activity. The activity state of the enzyme was greater by 3-fold in the muscle of starved compared with fed rats, but there was no significant difference between the activity states in the liver. There were no significant differences between protein expressions of BCKA dehydrogenase subunits (E(1)alpha, E(1)beta and E(2)) in tissues of fed and starved rats; the exceptions were a greater expression of E(1)alpha in the liver and a lower expression of E(1)beta in the skeletal muscle of starved rats. These differences in protein expressions were not accompanied with any difference in the mRNA expressions of genes encoding E(1)alpha and E(1)beta. The rate of inactivation of BCKA dehydrogenase, mediated by its associated kinase, was significantly slower in the skeletal muscle of starved rats but was the same in the liver. However, there was no significant difference between the protein or the mRNA expressions of the gene encoding BCKA dehydrogenase kinase in tissues of fed and starved rats. These results show that starvation increases the activity of BCKA dehydrogenase in the liver and skeletal muscle, and the mechanisms of increases in activity are posttranscriptional and involve cellular rather than the molecular mechanisms.


Asunto(s)
Regulación Enzimológica de la Expresión Génica , Cetona Oxidorreductasas/metabolismo , Hígado/enzimología , Complejos Multienzimáticos/metabolismo , Músculo Esquelético/enzimología , Inanición/metabolismo , 3-Metil-2-Oxobutanoato Deshidrogenasa (Lipoamida) , Adenosina Trifosfato/metabolismo , Animales , Activación Enzimática , Cetona Oxidorreductasas/química , Cetona Oxidorreductasas/genética , Cinética , Masculino , Complejos Multienzimáticos/química , Complejos Multienzimáticos/genética , Proteínas Quinasas/genética , Proteínas Quinasas/metabolismo , ARN Mensajero/análisis , Ratas , Ratas Sprague-Dawley , Inanición/enzimología
9.
Biochim Biophys Acta ; 1466(1-2): 372-8, 2000 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-10825457

RESUMEN

Renal lysosomes play a major role in catabolism of plasma proteins. Final products of this catabolism include dipeptides and tripeptides that must be exported to the cytosol for hydrolysis. The aim of the present study was to determine whether an oligopeptide transporter is present in the renal lysosomal membrane that could mediate this export. The existence of an oligopeptide transporter was probed with the uptake of glycylglutamine (Gly-Gln) by membrane vesicles prepared from renal lysosomes. Kinetic analysis showed the presence of a single transporter with a K(m) of 8.77 mM for the uptake of Gly-Gln. The Gly-Gln uptake was energized by the imposition of an inwardly directed proton gradient (pH(out) 5.0/pH(in) 7.3) and membrane potential (outside positive/inside negative) resulting in overshoot. The Gly-Gln uptake was inhibited by the presence of dipeptides and tripeptides, but not amino acids. Western blot analysis of lysosomal membrane proteins with Pept-1 (an oligopeptide transporter) antibody as the probe showed the presence of an immunoreactive protein. This immunoreaction was abolished when the antiserum was preabsorbed with the Pept-1 epitope (0.5 microg/ml). In conclusion, the present data show the existence of a low-affinity dipeptide transporter in the renal lysosomal membrane that appears to belong to the Pept family of transporters. The function of this transporter appears to be to prevent accumulation of dipeptides in renal lysosomes.


Asunto(s)
Proteínas Portadoras/metabolismo , Dipéptidos/farmacocinética , Riñón/metabolismo , Simportadores , Secuencia de Aminoácidos , Animales , Western Blotting/métodos , Relación Dosis-Respuesta a Droga , Membranas Intracelulares/metabolismo , Lisosomas/metabolismo , Masculino , Datos de Secuencia Molecular , Oligopéptidos/metabolismo , Concentración Osmolar , Transportador de Péptidos 1 , Conejos , Ratas , Ratas Sprague-Dawley , Factores de Tiempo
10.
Am J Physiol ; 277(4): E685-92, 1999 10.
Artículo en Inglés | MEDLINE | ID: mdl-10516128

RESUMEN

Rat cardiac and skeletal muscles, which have been used as model tissues for studies of regulation of branched-chain alpha-keto acid (BCKA) oxidation, vary greatly in the activity state of their BCKA dehydrogenase. In the present experiment, we have investigated whether they also vary in response of their BCKA dehydrogenase to a metabolic alteration such as diabetes and, if so, to investigate the mechanism that underlies the difference. Diabetes was produced by depriving streptozotocin-treated rats of insulin administration for 96 h. The investigation of BCKA dehydrogenase in the skeletal muscle (gastrocnemius) showed that diabetes 1) increased its activity, 2) increased the protein and gene expressions of all of its subunits (E(1)alpha, E(1)beta, E(2)), 3) increased its activity state, 4) decreased the rate of its inactivation, and 5) decreased the protein expression of its associated kinase (BCKAD kinase) without affecting its gene expression. In sharp contrast, the investigation of BCKA dehydrogenase in the cardiac muscle showed that diabetes 1) decreased its activity, 2) had no effect on either protein or gene expression of any of its subunits, 3) decreased its activity state, 4) increased its rate of inactivation, and 5) increased both the protein and gene expressions of its associated kinase. In conclusion, our data suggest that, in diabetes, the protein expression of BCKAD kinase is downregulated posttranscriptionally in the skeletal muscle, whereas it is upregulated pretranslationally in the cardiac muscle, causing inverse alterations of BCKA dehydrogenase activity in these muscles.


Asunto(s)
Diabetes Mellitus Experimental/enzimología , Cetona Oxidorreductasas/metabolismo , Complejos Multienzimáticos/metabolismo , Músculo Esquelético/enzimología , Miocardio/enzimología , 3-Metil-2-Oxobutanoato Deshidrogenasa (Lipoamida) , Animales , Diabetes Mellitus Experimental/genética , Activación Enzimática , Expresión Génica , Cetona Oxidorreductasas/genética , Masculino , Complejos Multienzimáticos/genética , Proteínas Quinasas/genética , Proteínas Quinasas/metabolismo , Ratas , Ratas Sprague-Dawley
11.
Metabolism ; 48(6): 681-4, 1999 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10381139

RESUMEN

The intestinal oligopeptide transporter, cloned as Pept-1, has major roles in the assimilation of dietary proteins and absorption of peptidomimetic medications. The initial aim of the present experiment was to investigate whether the functional expression of this transporter is affected by dietary intake. Functional expression was determined as the rate of uptake of glycylglutamine (Gly-Gln) by brush-border membrane vesicles (BBMVs) prepared from the jejunum of fed and fasted rats. Surprisingly, the rate of dipeptide uptake was greatly increased after 1 day of fasting. The subsequent aim of the experiment became the investigation of the mechanism of this alteration in transport, which showed that 1 day of fasting increased (1) the maximal Gly-Gln uptake (Vmax) by twofold without changing the Km of Gly-Gln uptake by BBMVs, (2) the amount of intestinal oligopeptide transporter (Pept-1) protein by threefold in the brush-border membrane, and (3) the abundance of Pept-1 mRNA by threefold in the intestinal mucosa. We conclude that 1 day of fasting increases dipeptide transport in rat intestine by increasing the population of Pept-1 in the brush-border membrane. The mechanism appears to be an increase in Pept-1 gene expression.


Asunto(s)
Proteínas Portadoras/metabolismo , Dipéptidos/metabolismo , Ayuno/metabolismo , Yeyuno/metabolismo , Simportadores , Animales , Transporte Biológico , Northern Blotting , Western Blotting , Absorción Intestinal , Yeyuno/ultraestructura , Masculino , Microvellosidades/metabolismo , Transportador de Péptidos 1 , Ratas , Ratas Sprague-Dawley , Regulación hacia Arriba
12.
Am J Physiol ; 276(4): C821-6, 1999 04.
Artículo en Inglés | MEDLINE | ID: mdl-10199812

RESUMEN

The intestinal oligopeptide transporter (cloned as Pept-1) has major roles in protein nutrition and drug therapy. A key unstudied question is whether expression of Pept-1 is hormonally regulated. In this experiment, we investigated whether insulin has such a role. We used a human intestinal cell monolayer (Caco-2) as the in vitro model of human small intestine and glycylglutamine (Gly-Gln) as the model substrate for Pept-1. Results showed that addition of insulin at a physiological concentration (5 nM) to incubation medium greatly stimulates Gly-Gln uptake by Caco-2 cells. This stimulation was blocked when genistein, an inhibitor of tyrosine kinase, was added to incubation medium. Studies of the mechanism of insulin stimulation showed the following. 1) Stimulation occurred promptly (30-60 min) after exposure to insulin. 2) There was no significant change in the Michaelis-Menten constant of Gly-Gln transport, but there was a nearly twofold increase in its maximal velocity. 3) Insulin effect persisted even when Golgi apparatus, which is involved in trafficking of newly synthesized Pept-1, was dismantled. 4) However, there was complete elimination of insulin effect by disruption of microtubules involved in trafficking of preformed Pept-1. 5) Finally, with insulin treatment, there was no change in Pept-1 gene expression, but the amount of Pept-1 protein in the apical membrane was increased. In conclusion, the results show that insulin, when it binds to its receptor, stimulates Gly-Gln uptake by Caco-2 cells by increasing the membrane population of Pept-1. The mechanism appears to be increased translocation of this transporter from a preformed cytoplasmic pool.


Asunto(s)
Proteínas Portadoras/genética , Proteínas Portadoras/metabolismo , Dipéptidos/farmacocinética , Insulina/farmacología , Mucosa Intestinal/metabolismo , Simportadores , Transporte Biológico/efectos de los fármacos , Brefeldino A/farmacología , Membrana Celular/metabolismo , Genisteína/farmacología , Humanos , Intestino Delgado/metabolismo , Cinética , Transportador de Péptidos 1 , ARN Mensajero/genética , Transcripción Genética/efectos de los fármacos , Células Tumorales Cultivadas
13.
Proc Assoc Am Physicians ; 110(4): 361-8, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9686684

RESUMEN

The initial objective of this study was to investigate whether the presence of dipeptide in the culture medium stimulates the uptake of dipeptide by a human intestinal cell line that expresses the oligopeptide transporter (Pept-1). The results showed that addition of glycylsarcosine (Gly-Sar) for 24 hr to the culture medium significantly increased the rate of glycylglutamine (Gly-Gln) uptake by Caco-2 cells. Furthermore, this stimulation in transport was also observed when Cefadroxil (beta-lactam antibiotic) instead of Gly-Gln was used as a probe but did not occur when Gly-Sar was added to the culture medium for only 2 hr or when Gly-Sar was substituted by a corresponding mixture of glycine plus sarcosine. The subsequent objective of the study was to investigate the mechanism of stimulation in transport described earlier. The results showed that the addition of Gly-Sar for 24 hr to the culture medium: (1) increased the Vmax of Gly-Gln transport by two-fold without affecting its Km, (2) increased the protein mass of Pept-1 by more than two-fold, (3) increased the abundance of Pept-1 mRNA by three-fold, and (4) had no effect on Gly-Gln transport when an inhibitor of trans-Golgi network (brefeldin) was added to the culture medium, but still increased the abundance of Pept-1 mRNA. In conclusion, the results show that dipeptides stimulate their own transport by increasing the membrane population of Pept-1. The molecular mechanism appears to be an increase in expression of the gene encoding Pept-1. A therapeutic application of the present results is that if bioavailability of orally administered peptidomimetic drugs is limited, patients may be tried on a high-protein diet to enhance their absorption.


Asunto(s)
Dipéptidos/metabolismo , Dipéptidos/fisiología , Intestino Delgado/metabolismo , Transporte Biológico Activo/efectos de los fármacos , Células CACO-2 , Glutamina/metabolismo , Glicina/metabolismo , Humanos , Intestino Delgado/citología , Cinética , Sarcosina/metabolismo
14.
Proc Assoc Am Physicians ; 110(1): 40-9, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9460082

RESUMEN

The key enzyme regulating oxidation of branched-chain keto acids (BCKAs) is BCKA dehydrogenase (BCKAD). We have previously shown that an increase in the activity of this enzyme accounts for the increased oxidation of leucine in the liver of diabetic rats. In the present experiment, we have investigated the mechanisms responsible for this increase in enzyme activity. These studies were performed 96 hours after the withdrawal of insulin therapy in rats made diabetic by an injection of streptozotocin. Diabetes increased the activity state (83% versus 97%, p < .01) as well as the total activity (78 versus 112 nmol/min/mg protein, p < .01) of BCKAD. The increase in the activity state was due to a 60% fall in the BCKAD kinase activity, which was the result of a 50% decrease in its protein mass. A coordinated increase (50%-70%) in protein mass of each BCKAD subunit (E1 alpha, E1 beta, and E2) accounted for the increase in the total activity of BCKAD. We conclude that diabetes increases the hepatic BCKAD activity by increasing its protein mass and also by decreasing that of its associated kinase. These alterations appear to occur posttranscriptionally, since diabetes had no effect on the gene expressions of BCKAD subunits (E1 alpha, E1 beta, and E2) or BCKAD kinase.


Asunto(s)
Diabetes Mellitus Experimental/metabolismo , Cetona Oxidorreductasas/metabolismo , Hígado/enzimología , Complejos Multienzimáticos/metabolismo , Proteínas Quinasas/metabolismo , Procesamiento Proteico-Postraduccional , 3-Metil-2-Oxobutanoato Deshidrogenasa (Lipoamida) , Animales , Modelos Animales de Enfermedad , Expresión Génica , Humanos , Cetona Oxidorreductasas/biosíntesis , Cetona Oxidorreductasas/genética , Masculino , Complejos Multienzimáticos/biosíntesis , Complejos Multienzimáticos/genética , Proteínas Quinasas/biosíntesis , Proteínas Quinasas/genética , ARN Mensajero , Ratas , Ratas Sprague-Dawley
15.
Gastroenterology ; 113(1): 332-40, 1997 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-9207295

RESUMEN

The oligopeptide transporter (Pept-1), which is located in the intestinal brush border membrane, provides a major mechanism for protein absorption in the human intestine. Expression cloning of the gene encoding Pept-1 has predicted a 78,810-kilodalton protein consisting of 708 amino acid residues and possessing 12 putative membrane-spanning domains. The characterization of its function by in vivo and in vitro studies has shown that (1) it transports dipeptides and tripeptides but not free amino acids or peptides with more than three amino acid residues, and (2) its driving force for uphill transport requires proton binding and presence of an inside-negative membrane potential. There has also been cloning of a membrane protein (HPT-1) which appears to be associated with the oligopeptide transporter. However, the nature of association has not yet been determined. A human intestinal cell line (Caco-2), which expresses Pept-1, has been used to investigate the effects of metabolic and pathological factors on dipeptide transport. These studies suggest that the insulin stimulates dipeptide transport by increasing membrane insertion of oligopeptide transporter from a preformed cytoplasmic pool, and cholera toxin decreases dipeptide transport by inhibiting the activity of Pept-1 through an increase in the intracellular concentration of adenosine 3',5'-cyclic monophosphate. Lastly, Pept-1 seems to play important roles in nutritional and pharmacological therapies; for example, it has allowed the use of oligopeptides as a source of nitrogen for enteral feeding and the use of oral route for delivery of peptidomimetic drugs such as beta-lactam antibiotics.


Asunto(s)
Proteínas Portadoras/química , Proteínas Portadoras/fisiología , Mucosa Intestinal/metabolismo , Simportadores , Células CACO-2 , Humanos , Transportador de Péptidos 1
16.
J Biol Chem ; 272(18): 11786-90, 1997 May 02.
Artículo en Inglés | MEDLINE | ID: mdl-9115234

RESUMEN

Accumulation of products of proteolysis (e.g. dipeptides) in lysosomes may have pathological consequences. In the present experiment we have investigated the existence of a dipeptide transporter in a membrane preparation of liver lysosomes using Gly-3H-Gln as the probe. The results showed that (a) there was transport of Gly-Gln into an osmotically reactive space inside the lysosomal membrane vesicles; (b) transport was stimulated by acidification (pH 5.0) of the external medium; (c) there was a coupling between transport of protons and Gly-Gln with a stoichiometry of 1:1; (d) the presence of both acidic pH and membrane potential was necessary for uphill transport of Gly-Gln; (e) a single transporter with a Km of 4.67 mM mediated the uptake of Gly-Gln; and (f) Gly-Gln uptake was inhibited by dipeptides and tripeptides but not by amino acids. The results suggest the presence of a low affinity proton-coupled oligopeptide transporter in the liver lysosomal membrane which mediates transfer of dipeptides from a region of low dipeptidase activity (intralysosome) to a region of high dipeptidase activity (cytosol). In this manner, the transporter provides an active mechanism for completion of the final stage of protein degradation.


Asunto(s)
Proteínas Portadoras/metabolismo , Dipéptidos/metabolismo , Membranas Intracelulares/metabolismo , Hígado/metabolismo , Lisosomas/metabolismo , Proteínas/metabolismo , Aminoácidos/farmacología , Animales , Fraccionamiento Celular , Dipéptidos/farmacología , Concentración de Iones de Hidrógeno , Membranas Intracelulares/efectos de los fármacos , Cinética , Lisosomas/efectos de los fármacos , Masculino , Concentración Osmolar , Ratas , Ratas Sprague-Dawley , Sodio/farmacología , Tritio
17.
Am J Physiol ; 272(5 Pt 1): E723-36, 1997 May.
Artículo en Inglés | MEDLINE | ID: mdl-9176169

RESUMEN

Assimilation of systemic oligopeptides (di- and tripeptides) is largely a function of kidneys. The most specific and unique mechanism utilized for the performance of this renal function is transport, followed by intracellular hydrolysis and then release of constituent amino acids to the systemic circulation. Among tissues examined (liver, kidney, intestine, and muscle), kidney is the only tissue capable of accumulating dipeptides in concentrations that are greater than their plasma concentrations. Kidney also is the tissue with the highest cytoplasmic dipeptidase activity. Intracellular accumulation is mediated by two transporters (Pept-1 and Pept-2), both of which have been recently cloned. These transporters use dipeptides and tripeptides as substrates and rely on protons and membrane potential for their driving force. Pept-1 is a low-affinity, high-capacity transporter, and Pept-2 is a high-affinity, low-capacity transporter. The nutritional and metabolic regulation of renal assimilation of oligopeptides is suggested by the selective decrease in dipeptide balance across the kidneys of starved human subjects and by the insulin stimulation of dipeptide transport by a renal cell line. Peptiduria has been observed in a variety of diseases, but the mechanism, except in genetic diseases affecting hydrolysis of oligopeptides, is not known. Finally, the capacity for active transport of oligopeptides and peptidomimetic drugs enables kidneys to play major roles in nutritional and pharmacological therapies.


Asunto(s)
Riñón/metabolismo , Oligopéptidos/metabolismo , Animales , Transporte Biológico , Proteínas Portadoras/genética , Clonación Molecular , Glutatión/metabolismo , Humanos , Hidrólisis , Riñón/fisiología , Oligopéptidos/química , Oligopéptidos/fisiología , Relación Estructura-Actividad
18.
Am J Physiol ; 271(3 Pt 1): E535-40, 1996 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8843748

RESUMEN

Glycylglutamine (Gly-Gln) is stable source of glutamine for parenteral nutrition. In the present study we have investigated whether this dipeptide is transferred intact across the human placenta. Although after 90 min of placental perfusion there was almost complete disappearance of Gly-Gln (100 microM) from the maternal compartment, only a small concentration of this dipeptide (< 6 microM) appeared in the fetal compartment. To investigate whether this transfer was due to transcellular transport, brush-border membrane vesicles of the human placenta were probed with [3H]Gly-Gln, which showed no uptake. To investigate whether hydrolysis was the mechanism of disappearance of Gly-Gln, the perfusion study was repeated with glycylsarcosine (Gly-Sar), which is resistant to hydrolysis. In sharp contrast to Gly-Gln, after 90 min of perfusion nearly 80% of Gly-Sar remained in the perfusate (half-life of 24 vs. 235 min). The rest of the Gly-Sar was recovered intact in the fetal compartment. The addition of Gly-Gln to the maternal compartment increased the accumulation of glycine, but not glutamine, in both the maternal and fetal compartments. In conclusion, our data suggest that 1) the mechanism of clearance of Gly-Gln by perfused human placenta is largely hydrolysis, whereas that of Gly-Sar is largely passive diffusion, and 2) the placenta has a greater preference for glutamine than for glycine.


Asunto(s)
Dipéptidos/metabolismo , Placenta/metabolismo , Femenino , Humanos , Intercambio Materno-Fetal , Perfusión , Embarazo
19.
Biochem J ; 317 ( Pt 2): 411-7, 1996 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-8713066

RESUMEN

We previously showed that the oxidation of branched-chain amino acids is increased in rats treated with clofibrate [Paul and Adibi (1980) J. Clin. Invest. 65, 1285-1293]. Two subsequent studies have reported contradictory results regarding the effect of clofibrate treatment on gene expression of branched-chain keto acid dehydrogenase (BCKDH) in rat liver. Furthermore, there has been no previous study of the effect of clofibrate treatment on gene expression of BCKDH kinase, which regulates the activity of BCKDH by phosphorylation. The purpose of the present study was to investigate the above issues. Clofibrate treatment for 2 weeks resulted in (a) a 3-fold increase in the flux through BCKDH in mitochondria isolated from rat liver, and (b) a modest but significant increase in the activity of BCKDH. However, clofibrate treatment had no significant effect on the mass of E1 alpha, E1 beta, and E2 subunits of BCKDH or the abundance of mRNAs encoding these subunits. On the other hand, clofibrate treatment significantly reduced the activity, the protein mass and the mRNA levels of BCKDH kinase in the liver. In contrast to the results obtained in liver, clofibrate treatment had no significant effect on any of these parameters of BCKDH kinase in the skeletal muscle. In conclusion, our results show that clofibrate treatment increases the activity of BCKDH in the liver and the mechanism of this effect is the inhibition of gene expression of the BCKDH kinase.


Asunto(s)
Clofibrato/farmacología , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Hipolipemiantes/farmacología , Cetona Oxidorreductasas/biosíntesis , Mitocondrias Hepáticas/efectos de los fármacos , Complejos Multienzimáticos/biosíntesis , Proteínas Quinasas/biosíntesis , 3-Metil-2-Oxobutanoato Deshidrogenasa (Lipoamida) , Animales , Cetona Oxidorreductasas/genética , Masculino , Mitocondrias Hepáticas/enzimología , Complejos Multienzimáticos/genética , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/enzimología , Proteínas Quinasas/genética , ARN Mensajero/análisis , Ratas , Ratas Sprague-Dawley
20.
Metabolism ; 44(10): 1243-6, 1995 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-7476278

RESUMEN

Chronic ethanol intake selectively increases concentrations of branched-chain amino acids (BCAA) in the liver. To determine whether a reduced oxidation plays a role in this effect, we measured substrate flux through branched-chain keto-acid (BCKA) dehydrogenase in livers of rats pair-fed liquid diets containing either 0% or 36% of total calories as ethanol for 21 days. Substrate (1.0 mmol/L ketoisocaproate [KIC]) fluxes in the liver of ethanol-fed and control rats were 225 +/- 18 and 319 +/- 27 mumol/h per whole liver (P < .05), respectively. We then studied whether this effect was due to either ethanol or the products of its metabolism, or to an alteration in the activity of BCKA dehydrogenase. Addition of ethanol (25 to 200 mmol/L) to the perfusion medium had no significant effect on the flux through BCKA dehydrogenase in the liver of control rats. Ethanol-fed rats had lower (P < .01) basal activity (0.84 +/- 0.11 v 1.39 +/- 0.12 U/g liver) and total activity (0.94 +/- 0.11 v 1.42 +/- 0.11 U/g liver) than control rats, but a similar activity state (90% +/- 4% v 99% +/- 4%) of BCKA dehydrogenase. In conclusion, chronic ethanol intake reduces the flux through liver BCKA dehydrogenase by decreasing the basal and total activity of BCKA dehydrogenase and not increasing the conversion of the enzyme to its inactive form.


Asunto(s)
Etanol/toxicidad , Cetona Oxidorreductasas/metabolismo , Hígado/enzimología , Complejos Multienzimáticos/metabolismo , 3-Metil-2-Oxobutanoato Deshidrogenasa (Lipoamida) , Administración Oral , Aminoácidos de Cadena Ramificada/metabolismo , Análisis de Varianza , Animales , Relación Dosis-Respuesta a Droga , Etanol/administración & dosificación , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Oxidación-Reducción , Consumo de Oxígeno , Ratas , Ratas Sprague-Dawley
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA